Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments

摘要: Survival rates for children with acute myeloid leukemia (AML) exceed 60 % when modern, intensified chemotherapeutic regimens and enhanced supportive care measures are employed. Despite well-recognized improvements in outcomes, primary refractory or relapsed pediatric AML yields significant morbidity mortality, improved understanding of this obstinate population along refined treatment protocols urgently needed. Although a number patients disease will achieve remission, long-term survival remain poor, efforts to identify therapies which improve OS under continuous investigation. The current fundamental goal such investigation is the achievement as complete remission possible without dose-limiting toxicities, progression hematopoietic stem cell transplantation thereafter. In review scope problem well emerging chemotherapy options be discussed.